ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY
GOTHENBURG, NE / ACCESS Newswire / February 26, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, today announces that the first patient has been dosed in a Phase Ib study with IRL757 - a potential new treatment for Parkinson's disease-related apathy. This event triggers a USD 3 million milestone payment to IRLAB, payable in instalments in 2026. The study is fully funded by IRLAB's development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) - an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.
"The progress in the clinical development of IRL757 as a potential new treatment for Parkinson's patients experiencing apathy triggers a USD 3 million milestone payment that will further strengthen IRLAB's financial position. The solid scientific and financial backing from our collaborator, MSRD, enables us to continue to develop this first-in-class drug candidate efficiently, with the aim to improve the quality of life for the vast number of persons who are currently lacking treatment options for this severely disabling condition," says Kristina Torfgård, CEO of IRLAB.
The safety, tolerability and signal finding Phase Ib study, LIFT-PD, which will include 75 patients with Parkinson's disease who experience apathy, will be conducted at 16 study sites in Germany, Bulgaria, Poland, and Spain.
Two previous Phase I studies, one in healthy young adults and one in healthy older adults aged 65 and above, both showed that IRL757 was well absorbed and provided good systemic exposure after 10 days of dosing. All participants completed both studies, and no serious adverse events were recorded.
Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability affecting a substantial proportion of people living with Parkinson's disease and other neurodegenerative diseases. Currently, there are no drugs on the market to treat apathy.
IRLAB and MSRD, a member of the global Otsuka family of pharmaceutical companies, formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment for apathy.
IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's unique ability to counteract disturbances in central nervous system nerve signaling proposed to underly apathy in several neurological conditions.
For more information
Kristina Torfgård, CEO
Phone: +46 730 60 70 99
E-mail: kristina.torfgard@irlab.se
This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-26 11:58 CET.
About IRL757
The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US).
IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders. IRL75, currently in Phase Ib, is being developed for the treatment of apathy in neurodegenerative disorders.
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.
Attachments
IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson's Disease
SOURCE: IRLAB Therapeutics
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/irlab-secures-milestone-payment-for-first-patient-dosed-in-phase-ib-s-1141861
